TY - JOUR
T1 - Rate of CD4+ Cell Count Increase over Periods of Viral Load Suppression
T2 - Relationship with the Number of Previous Virological Failures
AU - Trotta, Maria Paola
AU - Cozzi-Lepri, Alessandro
AU - Ammassari, Adriana
AU - Vecchiet, Jacopo
AU - Cassola, Giovanni
AU - Caramello, Pietro
AU - Vullo, Vincenzo
AU - Soscia, Fabrizio
AU - Chiodera, Alessandro
AU - Ladisa, Nicoletta
AU - Abeli, Clara
AU - Cauda, Roberto
AU - Buonuomi, Anna Rita
AU - Antinori, Andrea
AU - Monforte, Antonella D arminio
PY - 2010/8/15
Y1 - 2010/8/15
N2 - Background. Although the kinetics of CD+ cell counts have been extensively studied in antiretroviral-naive HIV-infected patients, data on individuals who have failed combination antiretroviral therapy (cART) are lacking. Methods. This analysis was based on the ICONA Foundation Study. Subjects with ≥1 episode of viral suppression after starting first-line cART were included (np3537). Following a viral rebound, patients who achieved another episode of viral suppression could reenter the analysis. The percentage of patients with an increase in CD+ cell count 1300 cells/mm3 was estimated using Kaplan-Meier techniques; the rate of CD+ cell count increase per year was estimated using a multivariable, multilevel linear model with fixed effects of intercept and slope. Multivariable models were also fitted to include several covariates. Results. The median time to reach a CD+ cell count increase 3 from baseline was significantly associated with the number of failed regimens: 34 months, 41 months, 51 months, and 45 months in subjects without evidence of previous virological failure, or 1, 2, or ≥3 previous virologically failed regimens, respectively (P <.001, by log-rank test). The annual estimated increases in CD+ cell count were 36 cells/mm3 (95% confidence interval [CI], 34-38 cells/mm3), 28 cells/mm3 (95% CI, 11-21 cells/mm3), 31 cells/mm3 (95% CI, 26-36 cells/ mm 3), and 26 cells/mm3 (95% CI, 18-33 cells/mm3), respectively. Differences in the annual CD+ cell count increase were observed between specific antiretrovirals. Conclusions. Subjects with ≥1 virological failure took a longer time to reach a CD+ cell count 1300 cell/ mm3 and had a slower annual increase than those without virological failure. Efforts should be made to optimize first-line cART, because this represents the best chance of achieving an effective CD+ response.
AB - Background. Although the kinetics of CD+ cell counts have been extensively studied in antiretroviral-naive HIV-infected patients, data on individuals who have failed combination antiretroviral therapy (cART) are lacking. Methods. This analysis was based on the ICONA Foundation Study. Subjects with ≥1 episode of viral suppression after starting first-line cART were included (np3537). Following a viral rebound, patients who achieved another episode of viral suppression could reenter the analysis. The percentage of patients with an increase in CD+ cell count 1300 cells/mm3 was estimated using Kaplan-Meier techniques; the rate of CD+ cell count increase per year was estimated using a multivariable, multilevel linear model with fixed effects of intercept and slope. Multivariable models were also fitted to include several covariates. Results. The median time to reach a CD+ cell count increase 3 from baseline was significantly associated with the number of failed regimens: 34 months, 41 months, 51 months, and 45 months in subjects without evidence of previous virological failure, or 1, 2, or ≥3 previous virologically failed regimens, respectively (P <.001, by log-rank test). The annual estimated increases in CD+ cell count were 36 cells/mm3 (95% confidence interval [CI], 34-38 cells/mm3), 28 cells/mm3 (95% CI, 11-21 cells/mm3), 31 cells/mm3 (95% CI, 26-36 cells/ mm 3), and 26 cells/mm3 (95% CI, 18-33 cells/mm3), respectively. Differences in the annual CD+ cell count increase were observed between specific antiretrovirals. Conclusions. Subjects with ≥1 virological failure took a longer time to reach a CD+ cell count 1300 cell/ mm3 and had a slower annual increase than those without virological failure. Efforts should be made to optimize first-line cART, because this represents the best chance of achieving an effective CD+ response.
UR - http://www.scopus.com/inward/record.url?scp=77955670919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955670919&partnerID=8YFLogxK
U2 - 10.1086/655151
DO - 10.1086/655151
M3 - Article
C2 - 20597690
AN - SCOPUS:77955670919
VL - 51
SP - 456
EP - 464
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 4
ER -